This page shows the latest mavacamten news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Camzyos (mavacamten) for use across NHS England and Wales in adults with symptomatic
BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia last year. ... BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia, announced last year.
BMS gained the rights to mavacamten as part of its acquisition of MyoKardia. ... BMS picked up mavacamten as part of its $13.1bn acquisition of MyoKardia, announced last year.
When compared to placebo, patients on mavacamten had greater reductions in post-exercise LVOT gradient as well as improved symptom scores. ... In addition to HCM, BMS is also set to explore the potential of mavacamten in additional indications, including
In the process, BMS will gain the rights to MyoKardia’s investigational treatment mavacamten, which is currently being developed as a treatment for obstructive hypertrophic cardiomyopathy (HCM), wherein the wall between
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
No results were found
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...